ArticleWorld journal of gastrointestinal oncology2010
New insights on cholangiocarcinoma.
Article in World journal of gastrointestinal oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Clinical and Imaging Features of a Focal Intrahepatic Biliary Stricture Visualized Only as Duct Dilatation.Journal of the Korean Society of Radiology · 2024Article
- Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mTOR signaling pathway in human cholangiocarcinoma QBC939 cells.Journal of gastrointestinal oncology · 2022Article
- Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.Oncology letters · 2019Article
- A novel mouse model of orthotopic extrahepatic cholangiocarcinoma confirmed with molecular imaging.Translational cancer research · 2019Article
- Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience.Langenbeck's archives of surgery · 2018Review
- The cholangiocyte primary cilium in health and disease.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS.Cancer cell · 2017Article
- Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.BMC cancer · 2016Article
- Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.Clinical and experimental immunology · 2016Article
- Mandibular metastasis of cholangiocarcinoma: A case report.Imaging science in dentistry · 2015Article
- DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.Medical oncology (Northwood, London, England) · 2014Article
- Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.ISRN hepatology · 2014Review
- A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.Annals of surgical oncology · 2014Article
- Article
- A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.Oncology letters · 2013Article
- The significance of genetics for cholangiocarcinoma development.Annals of translational medicine · 2013Review
- Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.PloS one · 2013Article
- Surgical management trends for cholangiocarcinoma in the USA 1998-2009.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2012Article
- Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.World journal of gastroenterology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a devastating cancer arising from the neoplastic transformation of the biliary epithelium. It is characterized by a progressive increase in incidence and prevalence. The only curative therapy is radical surgery or liver transplantation but, unfortunately, the majority of patients present with advanced stage disease, which is not amenable to surgical therapies. Recently, proposed serum and bile biomarkers could help in the screening and surveillance of categories at risk and in diagnosing CCA at an early stage. The molecular mechanisms triggering neoplastic transformation and growth of biliary epithelium are still undefined, but significant progress has been achieved in the last few years. This review deals with the most recent advances on epidemiology, biology, and clinical management of CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.